A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2018
Price : $35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 16 Jun 2018 Pooled analysis results from this, ORAL Scan, ORAL Sync, ORAL standard, ORAL step, OPAL broaden and OPAL beyond were presented at the 19th Annual Congress of the European League Against Rheumatism.
- 26 Apr 2018 Results of a post-hoc analysis published in the Rheumatology.